| Mark Goldberg, MD | |
|
741 Northfield Ave, Ste 205, West Orange, NJ 07052-1174 | |
| (973) 467-1544 | |
| (973) 467-9586 |
| Full Name | Mark Goldberg |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 37 Years |
| Location | 741 Northfield Ave, West Orange, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114914389 | NPI | - | NPPES |
| 4580303 | Medicaid | NJ | |
| 81670 | Other | AMERIGROUP | |
| ES474 | Other | OXFORD | |
| 4340667 | Other | AETNA | |
| 1K9390 | Other | HEALTHNET | |
| 52B941 | Other | WELLCHOICE | |
| 6312229006 | Other | CIGNA | |
| 010000352200 | Other | AMERICHOICE | |
| 0503191000 | Other | AMERIHEALTH | |
| 5710571 | Other | GHI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 50551 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Barnabas Medical Center | Livingston, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Barnabas Health Medical Group Pc | 9537316955 | 558 |
News Archive
Lord (Tariq) Ahmad of Wimbledon, FCDO Minister of State for South Asia and the Commonwealth, has announced the appointment of Jo Lomas as the UK's Envoy to the Commonwealth.
A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.
Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, has closed on a $30mm credit facility to fund accelerated business expansion and refinance existing indebtedness.
StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
› Verified 7 days ago
| Entity Name | Ekg Interpretation Group Limited |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265607162 PECOS PAC ID: 9830260108 Enrollment ID: O20080613000004 |
News Archive
Lord (Tariq) Ahmad of Wimbledon, FCDO Minister of State for South Asia and the Commonwealth, has announced the appointment of Jo Lomas as the UK's Envoy to the Commonwealth.
A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.
Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, has closed on a $30mm credit facility to fund accelerated business expansion and refinance existing indebtedness.
StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
› Verified 7 days ago
| Entity Name | Barnabas Health Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841557246 PECOS PAC ID: 9537316955 Enrollment ID: O20120820000951 |
News Archive
Lord (Tariq) Ahmad of Wimbledon, FCDO Minister of State for South Asia and the Commonwealth, has announced the appointment of Jo Lomas as the UK's Envoy to the Commonwealth.
A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.
Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, has closed on a $30mm credit facility to fund accelerated business expansion and refinance existing indebtedness.
StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Goldberg, MD 741 Northfield Ave, Ste 205, West Orange, NJ 07052-1174 Ph: (973) 467-1544 | Mark Goldberg, MD 741 Northfield Ave, Ste 205, West Orange, NJ 07052-1174 Ph: (973) 467-1544 |
News Archive
Lord (Tariq) Ahmad of Wimbledon, FCDO Minister of State for South Asia and the Commonwealth, has announced the appointment of Jo Lomas as the UK's Envoy to the Commonwealth.
A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.
Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, has closed on a $30mm credit facility to fund accelerated business expansion and refinance existing indebtedness.
StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
› Verified 7 days ago
Dr. Lincoln Miller, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1500 Pleasant Valley Way, Suite 201, West Orange, NJ 07052 Phone: 973-966-6400 Fax: 973-514-1587 | |
Dr. David P Dobesh, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 375 Mount Pleasant Ave, West Orange, NJ 07052 Phone: 973-731-9442 Fax: 973-731-2918 | |
Dr. Iftekhar Kadri, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 372 Valley Rd, West Orange, NJ 07052 Phone: 973-736-2600 Fax: 973-736-8355 | |
Dr. Natalie Johnson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 470 Prospect Ave, Suite 200, West Orange, NJ 07052 Phone: 973-243-0290 Fax: 973-243-1863 | |
Dr. Mahidhar Mahasamudram Reddy, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1199 Pleasant Valley Way, West Orange, NJ 07052 Phone: 973-830-7694 | |
Dr. Audrey B Radin, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 80 Main St Ste 300, West Orange, NJ 07052 Phone: 855-619-4448 Fax: 732-784-9918 |